Holen Sie sich die Stockscreener-App
12.34
0.65%
0.08
Handel nachbörslich:
12.45
0.11
+0.89%
Schlusskurs vom Vortag:
$12.26
Offen:
$12.21
24-Stunden-Volumen:
563.68K
Relative Volume:
2.29
Marktkapitalisierung:
$425.28M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-47.20M
KGV:
-7.8835
EPS:
-1.5653
Netto-Cashflow:
$-43.65M
1W Leistung:
+23.28%
1M Leistung:
-15.48%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$12.00
$13.43
1-Wochen-Bereich:
$9.57
$14.23
52-Wochen-Spanne:
$9.424
$27.50
Mbx Biosciences Inc Stock (MBX) Company Profile
Firmenname
Mbx Biosciences Inc
Sektor
Branche
Telefon
(317) 989-3100
Adresse
12406 HORESHAM STREET, CARMEL
Vergleichen Sie MBX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MBX
Mbx Biosciences Inc
|
12.34 | 425.28M | 0 | -47.20M | -43.65M | -1.5653 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.23 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Mbx Biosciences Inc Stock (MBX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-08 | Eingeleitet | Guggenheim | Buy |
| 2024-10-08 | Eingeleitet | JP Morgan | Overweight |
| 2024-10-08 | Eingeleitet | Jefferies | Buy |
| 2024-10-08 | Eingeleitet | Stifel | Buy |
Mbx Biosciences Inc Aktie (MBX) Neueste Nachrichten
The Future of MBX Biosciences Inc: Analyzing MBX - The InvestChronicle
P. Kent Hawryluk Acquires 50,000 Shares of MBX Biosciences, Inc. (NYSE:MBX) Stock - MarketBeat
MBX Biosciences Director Makes Bold Stock Move - TipRanks
MBX Biosciences to Participate in Upcoming February Investor Conferences - The Manila Times
MBX Biosciences CEO to Present at Three Major Healthcare Investor Conferences in February - StockTitan
16,400 Shares in MBX Biosciences, Inc. (NYSE:MBX) Purchased by Barclays PLC - Defense World
Geode Capital Management LLC Invests $579,000 in MBX Biosciences, Inc. (NYSE:MBX) - Defense World
Long-acting MBX 2109 may offer more convenient symptom relief - Hypoparathyroidism News
Early success for MBX in Phase I trial of GLP-1RA for hypoglycaemia - Yahoo Finance
MBX Biosciences' Investigational Drug For Weight Loss Surgery-Related Low Blood Sugar Shows Encouraging Action - AOL
MBX Biosciences (NYSE:MBX) Shares Gap DownTime to Sell? - MarketBeat
MBX 1416 shows promise in Phase 1 trial for hypoglycemia treatment - Investing.com India
MBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric Hypoglycemia - The Manila Times
MBX Biosciences Announces Positive Phase 1 Topline Results - GlobeNewswire
MBX Biosciences' Long-Acting GLP-1 Drug Shows Promise in Phase 1 Trial with Weekly Dosing - StockTitan
Barclays PLC Buys Shares of 16,400 MBX Biosciences, Inc. (NYSE:MBX) - Defense World
Jane Street Group LLC Makes New $690,000 Investment in MBX Biosciences, Inc. (NYSE:MBX) - Defense World
MBX Biosciences (NYSE:MBX) Trading Down 6.6%Time to Sell? - MarketBeat
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Biotech IPO Shares 2025 Climb In Trading Debuts After Deals Upsized - Browvopetshop
MBX Biosciences (NYSE:MBX) Stock Price Down 7.3%Time to Sell? - MarketBeat
MBX Biosciences (NYSE:MBX) Shares Gap Down – Should You Sell? - Defense World
Franklin Resources Inc. Invests $11.69 Million in MBX Biosciences, Inc. (NYSE:MBX) - MarketBeat
Teachers Retirement System of The State of Kentucky Makes New $694,000 Investment in MBX Biosciences, Inc. (NYSE:MBX) - MarketBeat
MBX Biosciences to Participate in 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
MBX Biosciences (NYSE:MBX) Trading 4.6% HigherHere's Why - MarketBeat
MBX Biosciences (NYSE:MBX) Shares Gap UpWhat's Next? - MarketBeat
The Manufacturers Life Insurance Company Invests $1.20 Million in MBX Biosciences, Inc. (NYSE:MBX) - MarketBeat
Wellington Management Group LLP Takes $74.26 Million Position in MBX Biosciences, Inc. (NYSE:MBX) - MarketBeat
Frazier Life Sciences Management L.P. Makes New $155.50 Million Investment in MBX Biosciences, Inc. (NYSE:MBX) - MarketBeat
Maven Securities LTD Makes New $1.30 Million Investment in MBX Biosciences, Inc. (NYSE:MBX) - MarketBeat
RA Capital Management L.P. Takes $39.26 Million Position in MBX Biosciences, Inc. (NYSE:MBX) - MarketBeat
MBX Biosciences Announces MBX 2109 Phase 1 Study Results Published in The Journal of Clinical Endocrinology and Metabolism - The Manila Times
MBX Biosciences Announces MBX 2109 Phase 1 Study Results - GlobeNewswire
NEA Management Company LLC Invests $93.90 Million in MBX Biosciences, Inc. (NYSE:MBX) - MarketBeat
MBX Biosciences (NYSE:MBX) Shares Down 3.6% – Should You Sell? - Defense World
MBX Biosciences (NYSE:MBX) Shares Down 3.6%Time to Sell? - MarketBeat
MBX Biosciences (NYSE:MBX) Trading Up 6.5%Still a Buy? - MarketBeat
MBX Biosciences completes phase 1 trial of diabetes drug By Investing.com - Investing.com Canada
MBX Biosciences completes phase 1 trial of diabetes drug - Investing.com India
Finanzdaten der Mbx Biosciences Inc-Aktie (MBX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Mbx Biosciences Inc-Aktie (MBX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Mathers Edward T | Director |
Sep 16 '24 |
Buy |
16.00 |
500,000 |
8,000,000 |
3,614,486 |
| BASKETT FOREST | 10% Owner |
Sep 16 '24 |
Buy |
16.00 |
500,000 |
8,000,000 |
3,614,486 |
| Behbahani Ali | 10% Owner |
Sep 16 '24 |
Buy |
16.00 |
500,000 |
8,000,000 |
3,614,486 |
| Chang Carmen | 10% Owner |
Sep 16 '24 |
Buy |
16.00 |
500,000 |
8,000,000 |
3,614,486 |
| Florence Anthony A. Jr. | 10% Owner |
Sep 16 '24 |
Buy |
16.00 |
500,000 |
8,000,000 |
3,614,486 |
| Makhzoumi Mohamad | 10% Owner |
Sep 16 '24 |
Buy |
16.00 |
500,000 |
8,000,000 |
3,614,486 |
| Walker Paul Edward | 10% Owner |
Sep 16 '24 |
Buy |
16.00 |
500,000 |
8,000,000 |
3,614,486 |
| Yang Rick | 10% Owner |
Sep 16 '24 |
Buy |
16.00 |
500,000 |
8,000,000 |
3,614,486 |
| SANDELL SCOTT D | 10% Owner |
Sep 16 '24 |
Buy |
16.00 |
500,000 |
8,000,000 |
3,614,486 |
| ORBIMED ADVISORS LLC | Director |
Sep 16 '24 |
Buy |
16.00 |
750,000 |
12,000,000 |
3,158,428 |
1.09%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):